BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC

Bain Capital Life Sciences Investors, LLC ("BCLSI") is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iii) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the (a) sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP and (b) the managing member of BCLS Fund III Investments GP, LLC, which is the general partner of BCLS Fund III Investments, LP. The information included on the Information Table with respect to the holdings of Annexon Inc. ("ANNX"), Dianthus Therapeutics, Inc. ("DNTH"), NewAmsterdam Pharma Company NV ("NAMS"), Olema Pharmaceuticals, Inc. ("OLMA"), Savara Inc. ("SVRA"), Solid Biosciences, Inc. ("SLDB"), X4 Pharmaceuticals, Inc. ("XFOR") and Xilio Therapeutics, Inc. ("XLO") reflect the exercise of warrants and/or pre-funded warrants held by affiliates of BCLSI after giving effect to provisions that prevent the exercise of such securities if the beneficial ownership of such persons would exceed 9.99% of the underlying security following such exercise. As of March 31, 2025, affiliates of BCLSI held an aggregate of 4,474,126 shares of ANNX common stock, 1,689,374 shares of DNTH common stock, 10,473,913 ordinary shares of NAMS, 6,696,640 shares of OLMA common stock, 14,101,352 shares of SVRA common stock, 5,034,582 shares of SLDB common stock, 14,879,809 shares of XFOR common stock and 2,805,413 shares of XLO common stock.